The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Constellation Pharmaceuticals Inc. COM 210373106 61,437 2,626,631 SH   SOLE   0 2,626,631 0
Revolution Medicines Inc COM 76155X100 164,262 3,580,252 SH   SOLE   0 3,580,252 0
RAPT Therapeutics Inc COM 75382E109 86,262 3,885,679 SH   SOLE   0 3,885,679 0
ORIC Pharmaceuticals Inc. COM 68622P109 116,820 4,768,181 SH   SOLE   0 4,768,181 0
NGM Biopharmaceuticals Inc COM 62921N105 447,565 15,396,116 SH   SOLE   0 15,396,116 0
Nurix Therapeutics Inc COM 67080M103 167,368 5,383,333 SH   SOLE   0 5,383,333 0